Julie Laurin
Corporate Officer/Principal chez Alethia Biotherapeutics, Inc.
Profil
Julie Laurin is a professional who currently works as the Director of Preclinical Drug Development at Alethia Biotherapeutics, Inc. She previously worked as the Director of Preclinical & Clinical Research at BELLUS Health, Inc. and as the Vice President of Business Development at DAVIDsTEA, Inc. from 2019 to 2020.
Dr. Laurin holds a doctorate degree from the University of Montréal.
Postes actifs de Julie Laurin
| Sociétés | Poste | Début |
|---|---|---|
Alethia Biotherapeutics, Inc.
 Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | Corporate Officer/Principal | - |
Anciens postes connus de Julie Laurin
| Sociétés | Poste | Fin |
|---|---|---|
| DAVIDSTEA INC. | Corporate Officer/Principal | 01/05/2020 |
| BELLUS HEALTH | Corporate Officer/Principal | - |
Formation de Julie Laurin
| University of Montréal | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| DAVIDSTEA INC. | Consumer Non-Durables |
| Entreprise privées | 2 |
|---|---|
BELLUS Health, Inc.
 BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
Alethia Biotherapeutics, Inc.
Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | Health Technology |
